Académique Documents
Professionnel Documents
Culture Documents
Poised
Disclaimer
This IR Presentation contains forward-looking statements that are based on managements expectations, estimates, projections and assumptions. Actual results may differ from those we project and may be affected by the business environment, government regulation and legislation, financial market movement, or other factors. All forward-looking statements speak only as of the date of this report. The company does not undertake any
Leading Global Life Sciences
obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report. The Company has adopted its financial statements under International Financial Reporting Standards (IFRS) in 2010.
Slide 2
Agenda
Overview & Financial Highlight Product Sales & Pharma Div. R&D Pipeline Growth Pathway
Slide 3
Opening remarks
Slide 4
Who we are
1. R&D center established in 1984 2. Demerged from LG Chem. in 2002 3. One of LG Group affiliate
(Bil KRW)
Business Domain
- Revenues Breakdown (FY 2009)
Pharmaceutical Div. 270
(83%)
Vx Rx
30%, LG corp.* Market Cap. 1Tn KRW 11%, Mirae Asset 4%, National Pension Fund Dx
Others
Domestic 55%
Overseas 45%
Slide 5
12%
9%
4%
4%*
360
4XX
221
2006
2007
2008
2009
2010(E)
2011(E)
Slide 6
Strong Profit
Solid improvement of financial data
EPS
(Unit: KRW)
ROE
Profit
10
2009
1,627
Profitable Growth
15%~
2008
Leading Global Life Sciences
902
66% CAGR 66% CAGR
09
9%
2007
187*
08
2006
353
6%
Asset Utilization
Slide 7
* Excluding one-off milestone
Product sales
Growth Driver 7 emerging markets Diversified Portfolio
Policy Risk
Up 12%
Product Sales
(2009)
163
Up 7% 78 Up 160% 16
Up 8% 57
Biologics
Product
1st gen. Bio-drug (hGH. EPO. FSH)
Chemical Synthetics
CV franchise
Others
Diagnostic Medical Aesthetics* Contrast agent Functional food Others
Fine chem.
API Intermediate
Agro-chemicals
Slide 8
Pharmaceutical Division
High growth potential in emerging markets New growth driver in new therapeutic area
Product Sales
International Domestic (Bil KRW)
Growth Strategy
International
298b 260b
113b
222b
110b 88b
Leading Global Life Sciences
($80M) ($89M)
($103M)
Mexico
MENA
(Subsidiary/Branch)
India
Brazil
185b
Domestic
Diagnostic 35b
Medical Aesthetics
150b 134b
6b
2008
2009
2010(E)
2008 2009 2010(E)
Slide 9
Slide 10
* NASH : Non-Alcoholic SteatoHepatitis ** Diphtheria, Tetanus toxoids, Pertussis - Hepatitis B - Haemophlis Influenzae type B
Caspase Inhibitor
Advancing therapy for liver diseases First-in-class opportunity
Deal Structure
Year
L/O
Mechanism of action
Direct suppression of unwanted apoptotic liver cell death by potent inhibition of caspase, the major player for hepatic apoptosis
Slide 11
SR-hGH
Building on First-In-Class opportunity in US market
Pathways to US market
2009 Finalizing Launch plan 2010 2011 2012
US FDA Approval
EU
- Co-Marketing - Out-licensing
Slide 12
Growth Pathway
Geographical movement from domestic, emerging to US/EU markets
Stabilization
Expanding
Revs. Growth ~15% CAGR
Value - Generating
Revs. Growth 20% ~ CAGR
Performance
2nd Wave
In-organic Growth
US/EU
(Innovative Drugs)
Leading Global Life Sciences
1st Wave
Seven Emerging
(Bio-similar, Vaccine) Domestic (New product line-up)
2011
2015
US/EU
Domestic
40%
Emerging
320b
Leading Global Life Sciences
Emerging
40%
55%
Growth Catalysts SR-hGH (2011) 5 in 1 Vaccine (2013) DPP-IV (2013) HBV (2014) BEPO (2014) mAb Biosimilar (2014) Caspase Inhibitor (2015)
Slide 14
40% 5%
US/EU
20%
2009
2015(E)
www.lgls.com
Sales Costs of sales SG&A (excl. R&D) R&D expenses Operating Income
(As % of sales)
21.6 15.2
(5.4%)
32.8 27.4
(8.3%)